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Abstract
Background:  Atypical antipsychotics are widely used in the treatment of bipolar disorders.
Amisulpride is an atypical antipsychotic that has been proven to be effective in treatment of
schizophrenia, major depressive disorder and, more recently, acute mania. At the moment,
however, no study has assessed the effectiveness of this compound in maintenance therapy of
bipolar disorders. The purpose of this study was to assess the long-term effectiveness of
amisulpride in combination with standard treatments in patients with bipolar I disorder who have
shown inadequate responses to ongoing standard therapies.
Methods: 
The study enrolled fourteen bipolar I outpatients, not responding to ongoing standard therapy.
Three patients discontinued treatment but 11 were followed-up for 11.7 ± 8.2 months before
(range 3–24 months) and 5.2 ± 2.7 months after the introduction of amisulpride (range 3–9
months). Relapse rates before and during treatment with amisulpride were calculated in
accordance to an increase of 1 or more in Clinical Global Impressions Scale-Bipolar Version (CGI-
BP) score that was accompanied by a change in therapy or to an exacerbation of the symptoms
that required hospitalization.
Results: A statistically significant decrease in overall relapse rate was observed during the period
of amisulpride therapy compared with months previous to the introduction of amisulpride. The
relative risk of relapse in the absence of amisulpride therapy was 3.1 (χ2 = 4.2, P < 0.05). Similarly,
the rates of manic/mixed and depressive relapse were decreased but only manic episodes reached
statistical significance (RR = 5.3, χ2 = 5.2, P < 0.02).
Discussion and conclusion: This open-label study suggests that long-term therapy with
amisulpride may benefit patients by improving global symptoms of bipolar disorder and reducing
the rate of manic/mixed relapses. Large, randomized, double-blind, placebo-controlled studies are
needed to explore the benefits of adding long-term amisulpride to standard therapies for bipolar
disorder.
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Background
Bipolar disorder is a very common mood disorder charac-
terized by recurrent episodes of depression, mania, and/or
mixed symptom states. These episodes cause unusual and
extreme shifts in mood, energy, and behaviour that inter-
fere significantly with normal, healthy functioning and
strongly affects the quality of life and social functioning.
Type I bipolar disorder is the most severe and usually
chronic form of this disorder. The essential treatment of
this affection in adults involves drugs potentially effective
in controlling mania, in preventing recurrences of manic
and depressive episodes and, after completing an acute
phase of treatment, in maintaining a stable remission.
Unfortunately longitudinal studies have proven that a
large number of patients keep presenting the former
symptoms, even though treated with polytherapy. Nowa-
days atypical antipsychotics are increasingly used as mood
stabilizers during acute depressive and manic phases and
are preferably used instead of the traditional ones for
causing less side-effects [1]. Amisulpride is a highly toler-
able atypical antipsychotic that has been reported to be
effective in treatment of schizophrenia [2], major depres-
sive disorder [3] and, more recently, acute mania [4]. At
low doses, it increases dopaminergic transmission by pref-
erentially blocking D2 and D3 presynaptic receptors; the
latter property has been used in clinical trials as an addi-
tional therapy to lithium in depressed bipolar patients [5].
At the moment, however, no experimental study has
assessed the effectiveness of this compound in mid-term
maintenance therapy. The purpose of this study was to
assess the long-term effectiveness of amisulpride in com-
bination with standard treatments in patients with bipo-
lar I disorder who have shown inadequate responses to
ongoing standard therapies.
Methods
The study enrolled fourteen outpatients with type I bipo-
lar DSM-IV TR [6] disorder (8 men and 6 women, age 42.3
± 17.8 years), not responding to ongoing standard ther-
apy. They were treated with additional amisulpride.
Exclusion criteria included pregnancy and breastfeeding
in women, hyperprolactinaemia, breast and pituitary
tumors, pheochromocytoma, type Ia and III antiarrhyth-
mics use and a recent history of alcohol or drug abuse in
both men and women.
Total observation period varied from 6 to 33 months and
each patient was examined at least once 3 months before
and 3 months after the introduction of amisulpride as an
additional therapy [11.7 ± 8.2 (Mean ± Standard Devia-
tion) months before (range 3–24 months) and 5.2 ± 3.9
months after the introduction of amisulpride (range 3–9
months)]. Patients were examined at least once every two
months and no less than eight times a year to assess
response and side-effects, to record adherence to medica-
tion, and to adjust doses as necessary. Patients were rated
by the same clinician throughout the study period.
Patients could be withdrawn from the study at their
request or on the basis of clinical judgment or because of
abnormal safety assessments. Psychopathological evalua-
tion and severity assessments were performed at baseline
and at every examination. DSM-IV-TR [6] manic and
depressive episodes incidence rates were measured before
and after introducing amisulpride.
Relapse rates before and during treatment with amisul-
pride were calculated in accordance to an increase of 1 or
more in Clinical Global Impressions Scale-Bipolar Ver-
sion (CGI-BP) [7] score that was accompanied by a
change in therapy or to an exacerbation of the symptoms
who required hospitalization. Mean CGI-BP scores were
calculated by comparing T-1 (3 months before the intro-
duction of amisulpride as an additional therapy), T0
(baseline) and T1 (3 months after the introduction of
amisulpride as an additional therapy).
Amisulpride was administered in combination with the
outgoing therapy with a dosage ranging between 200 and
800 mg (mean 450 ± 232.9) in 10 patients with predom-
inant manic symptoms and in 4 euthymic patients for
whom it was necessary to replace the previously-used
antipsychotics (N = 3 haloperidol, N = 1 risperidone) due
to extrapyramidal symptoms (N = 1) or to excessive seda-
tion (N = 3). Dosage adjustments were provided if neces-
sary.
Results
As 3 patients (2 women) discontinued the trial in the first
two weeks because of side effects, the follow-up has been
conducted on 11 patients for a duration of 11.7 ± 8.2
months before the introduction of amisulpride as addi-
tional therapy (range 3–24 months) and 5.2 ± 2.7 months
after the introduction of amisulpride in therapy (range 3–
9 months).
A statistically significant decrease in overall relapse rate
was observed during the period of amisulpride therapy
compared with months previous to the introduction of
amisulpride from 21 relapse events per 129 person-
months (incidence 0.16 per month) to 3 relapse events
per 57 person-months (0.05) (figure 1). The relative risk
of relapse in the absence of amisulpride therapy was 3.1
(χ2 = 4.2, P < 0.05).
Similarly, the rates of manic/mixed relapse and depressive
relapse were decreased but only the differences of manic/
mixed reached the statistical significance (figure 1). Manic
or mixed relapses occurred at a rate of 15 events per 129
person-months (incidence 0.11) in the follow-up beforeClinical Practice and Epidemiology in Mental Health 2006, 2:19 http://www.cpementalhealth.com/content/2/1/19
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amisulpride therapy compared with 1 event per 57 per-
son-months (0.02) during amisulpride therapy, for a rela-
tive risk of relapse of 5.3 (χ2 = 5.2, P < 0.02).
Depressive relapses occurred at a rate of 6 events per 129
person month-years (0.05) before initiation of amisul-
pride therapy versus 2 events per 57 person-months
(0.04) during amisulpride therapy, for a relative risk of
relapse of 1.4 (χ2 = 0.22, NS). The two cases of depres-
sion, required dosage of amisulpride to be decreased to 50
mg/day.
Improvements in mean CGI-BP score were observed com-
paring the mean score 3 months before (4.45 ± 0.93
[Mean ± Standard Deviation]), at baseline (5.00 ± 1.118)
and 3 months after amisulpride introduction (3.82 ±
1.17, F = 3.5 (DF 2,30,32), P < 0.05; before vs baseline F
= 1.47 (DF 1,20,21), P = 0.239; after vs baseline F = 5.5
(DF 1,20,21), P = 0.029 (figure 2).
Three subjects dropped out due to the side effects in the 2
weeks before the introduction of amisulpride (2 for aka-
thisia [both female], 1 for sedation). The most frequent
side effects reported during the follow-up period were
mild. These side effects were: sedation (18.2%, 2
patients), weight gain (18.2%, 2 patients), and tremor
(9.1%, 1 patient). There were no incidents of tardive dys-
kinesia. One patient discontinued amisulpride therapy
after 1 year of therapy due to amenorrhea.
Discussion
Patients with bipolar I disorder who have inadequate
responses to standard pharmacological therapy remain a
common problem, despite the wide array of psychotropic
agents that may be utilized [8]. This open-label study sug-
gests that long-term therapy with amisulpride may benefit
patients by improving global symptoms of bipolar disor-
der and reducing the rate of manic/mixed relapses. In this
study, treatment with amisulpride for 12–36 weeks was
associated with significant improvements in relapse rates.
These results, while in agreement with a recent open pro-
spective study that established significant improvements
in manic symptoms [4], also suggest that the treatment
effect observed with amisulpride is maintained in the
long-term.
For each patient, long-term amisulpride treatment was
added to ongoing medication, which included traditional
mood stabilizers (lithium, lamotrigine, carbamazepine
and oxcarbazepine) but no patients were taking dival-
proex or antipsychotic agents. While polypharmacy with
several kinds of psychotropic therapies is common in
adults and children with bipolar disorder in the commu-
nity [9,10], systematic studies of long-term therapy did
not evaluate amisulpride as adjunctive therapy. This study
showed that adding amisulpride to a variety of ongoing
stabilizers was well tolerated and associated with a reason-
able low incidence of adverse events over the long term.
Some of our study data, and in particular the overcoming
of depressive episodes after decreasing the amisulpride
dosage, suggest that this compound may be effective as an
antidepressant at low doses and as an antimanic at high
doses, properties that could be used in long-term treat-
ment of the bipolar disorder.
Although the cause is unknown, several studies have sug-
gested an increased rate of antipsychotic-induced tardive
dyskinesia and extrapyramidal symptoms (EPS) in
patients with affective disorders compared with patients
with schizophrenia [11,12]. Of particular importance for
patients with affective disorders, no increase in tardive
dyskinesia and low incidence of EPS was reported during
amisulpride therapy in this study. CGI-BP Score after follow up Figure 2
CGI-BP Score after follow up.
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This study has a number of limitations, including a small
sample size and the absence of a control group. Further-
more, the design of an open-label study does not include
randomization techniques and blinding of investigators
to patient status, which may introduce assessment bias.
Nevertheless, large, randomized, double-blind, placebo-
controlled studies are needed to explore the benefits of
adding long-term amisulpride to standard therapies for
bipolar disorder.
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